OncoSec to Present at ThinkEquity Conference 2019

Apr 29, 2019 8:00am EDT

OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors

Apr 24, 2019 8:00am EDT

OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer

Apr 23, 2019 8:00am EDT

OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center

Apr 17, 2019 8:00am EDT

OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12

Apr 10, 2019 8:00am EDT

OncoSec to Present at H.C. Wainwright Global Life Sciences Conference

Apr 09, 2019 8:00am EDT

OncoSec’s KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec’s Technology and Provides Updates on TAVO’s Clinical Progress

Apr 08, 2019 8:00am EDT

OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting

Apr 02, 2019 8:00am EDT

OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO™ in Refractory Metastatic Melanoma

Apr 01, 2019 8:00am EDT

OncoSec To Host Key Opinion Leader Symposium On April 5, 2019

Mar 27, 2019 8:16am EDT